Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry

Figure 1

1-year major adverse limb events (MALE) and repeat revascularization for femoropopliteal (FP) non-in-stent restenosis and in-stent restenosis (ISR) groups.